{"id":"NCT02347891","sponsor":"Northwell Health","briefTitle":"Belimumab in Idiopathic Inflammatory Myositis","officialTitle":"Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2015-01","primaryCompletion":"2020-11","completion":"2020-11","firstPosted":"2015-01-28","resultsPosted":"2024-02-09","lastUpdate":"2024-02-09"},"enrollment":17,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Myositis"],"interventions":[{"type":"DRUG","name":"Belimumab","otherNames":["Benlysta"]},{"type":"DRUG","name":"Placebo","otherNames":["Saline IV bag"]}],"arms":[{"label":"Belimumab + Standard of Care","type":"EXPERIMENTAL"},{"label":"Placebo + Standard of Care","type":"ACTIVE_COMPARATOR"}],"summary":"The goal of the trial is to evaluate the efficacy and safety of belimumab as a maintenance therapy in adults with refractory Idiopathic inflammatory myositis (IIM) as compared with standard of care. This is a multicentre double-blind, placebo-controlled trial.","primaryOutcome":{"measure":"Response Rate During Randomized Phase","timeFrame":"40 weeks","effectByArm":[{"arm":"Arm 1 (Belimumab + SoC (Randomized Phase and Open Label Phase)","deltaMin":3,"sd":null},{"arm":"Arm 2 (Placebo + SoC (Randomized Phase) Followed by Belimumab + SoC (Open Label Phase)","deltaMin":1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.60"},{"comp":"OG000 vs OG001","p":"0.61"},{"comp":"OG000 vs OG001","p":"0.23"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["37326854"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":10},"commonTop":["Upper respiratory infection","rash","Urinary Tract Infection","Gout flare","fatigue and lightheadedness"]}}